Cost-Effectiveness of Once-Weekly Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in the UK

被引：0
|
作者：
Muszbek, N. [1 ]
Angdembe, A. [1 ]
Garcia-Vidal, C. [2 ]
Bielicka, I [3 ]
Abrams, K. [1 ]
Tolley, K. [4 ]
Ruhnke, M. [5 ]
Lebmeier, M.
Hawkins, N. [1 ]
Manamley, N. [3 ]
Dickerson, S. [3 ]
机构：
[1] Visible Analyt, Oxford, Oxon, England
[2] Hosp Clin Barcelona, Barcelona, Catalonia, Spain
[3] Mundipharma Res Ltd, Cambridge, Cambs, England
[4] Tolley Hlth Econ, Buxton, DBY, England
[5] Helios Klinikum Aue, Aue Bad Schlema, Sachsen, Germany
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE332
引用
下载
收藏
页码：S115 / S115
页数：1
相关论文
共 50 条
  • [41] Once-weekly semaglutide vs existing once-weekly glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of Type 2 diabetes: Long-term cost-effectiveness analyses in the UK setting
    Viljoen, A.
    Hoxer, C. S.
    Johansen, P.
    Malkin, S. J. P.
    Hunt, B.
    Bain, S. C.
    DIABETIC MEDICINE, 2019, 36 : 134 - 134
  • [42] Rezafungin efficacy and safety in immunocompromised patients: subanalyses of the phase 3 trial in treatment of candidemia and invasive candidiasis
    Sandison, T.
    Ramos-Martinez, A.
    Kim, Y. K.
    Chai, L.
    Slavin, M.
    SWISS MEDICAL WEEKLY, 2022, 152 : 11S - 12S
  • [43] Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia
    Malkin, Samuel J. P.
    Russel-Szymczyk, Monika
    Liidemann, Girtel
    Volke, Vallo
    Hunt, Barnaby
    DIABETES THERAPY, 2019, 10 (01) : 159 - 176
  • [44] The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK
    Viljoen, Adie
    Chubb, Barrie
    Malkin, Samuel J. P.
    Berry, Sasha
    Hunt, Barnaby
    Bain, Stephen C.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2023, 24 (06): : 895 - 907
  • [45] The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK
    Adie Viljoen
    Barrie Chubb
    Samuel J. P. Malkin
    Sasha Berry
    Barnaby Hunt
    Stephen C. Bain
    The European Journal of Health Economics, 2023, 24 : 895 - 907
  • [46] Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia
    Samuel J. P. Malkin
    Monika Russel-Szymczyk
    Girtel Liidemann
    Vallo Volke
    Barnaby Hunt
    Diabetes Therapy, 2019, 10 : 159 - 176
  • [47] Cost-effectiveness analysis of the therapy for the invasive Candidiasis in Colombia
    Molina, F. J.
    Cortes, J. A.
    Caceres, H. A.
    Soto, R.
    Lemos Luengas, E. V.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2010, 14 : E123 - E123
  • [48] Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting
    Martin, Virginia
    Vidal, Josep
    Malkin, Samuel J. P.
    Hallen, Nino
    Hunt, Barnaby
    ADVANCES IN THERAPY, 2020, 37 (10) : 4427 - 4445
  • [49] COST-EFFECTIVENESS ANALYSIS OF ANTIFUNGAL TREATMENTS AVAILABLE IN COLOMBIA FOR THE TREATMENT OF INVASIVE CANDIDIASIS
    Molina, F. J.
    Cortes, J. A.
    Soto, R.
    Lemos, E., V
    Gutierrez-Ardila, M., V
    Nunez, S. M.
    VALUE IN HEALTH, 2012, 15 (04) : A242 - A242
  • [50] Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis
    Georg Auzinger
    E. Geoffrey Playford
    Christopher N. Graham
    Hediyyih N. Knox
    David Weinstein
    Michal Kantecki
    Haran Schlamm
    Claudie Charbonneau
    BMC Infectious Diseases, 15
12345